NCT03347838View on ClinicalTrials.gov

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 30, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Bronchial DysplasiaTobacco SmokingHistory of Non-Small Cell Lung CancerHistory of Head and Neck Cancer
Interventions
DRUG

Nivolumab

Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Trial Locations (2)

80045

University of Colorado Anschutz Medical Campus, Aurora

80220

Denver VA Hospital, Denver

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Colorado, Denver

OTHER